Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLRK1 | P26718 | 11/20 | 0.49 |
| ▸ | MICA | Q29983 | 11/20 | 0.49 |
| ▸ | RAET1L | Q5VY80 | 11/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.45 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283605 | 0.89 | ITGA5 (0.43) | KLRK1MICARAET1LMTORITGA5 | |
| SCHEMBL19283548 | 0.89 | ITGA5 (0.43) | KLRK1MICARAET1LMTORITGA5 | |
| SCHEMBL19283712 | 0.87 | MTOR (0.50) | MTORITGA5ITGB6ITGB8NPC1 | |
| SCHEMBL19283585 | 0.87 | MTOR (0.47) | MTORITGA5ITGB6ITGB8NPC1 | |
| SCHEMBL19283521 | 0.85 | ITGA5 (0.42) | KLRK1MICARAET1LMTORITGA5 | |
| SCHEMBL19283578 | 0.83 | ITGA5 (0.44) | KLRK1MICARAET1LMTORITGA5 | |
| SCHEMBL20744505 | 0.82 | ITGA5 (0.45) | MTORITGA5ITGB6ITGB8NPC1 | |
| SCHEMBL30645021 | 0.82 | ITGA5 (0.45) | MTORITGA5ITGB6ITGB8NPC1 | |
| SCHEMBL21821293 | 0.82 | ITGA5 (0.46) | KLRK1MICARAET1LMTORITGA5 | |
| SCHEMBL19283810 | 0.82 | KLRK1 (0.53) | KLRK1MICARAET1LMTORITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | claimed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | claimed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | claimed |
| CN-111344281-B | Potassium channel inhibitors substituted benzimidazoles | 阿塞西翁制药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-07-09 | — | — | US | disclosed |
| EP-3668841-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034603-A1 | SUBSTITUTED BENZIMIDAZOLES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216398-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | KLRK1 1057/4885MICA 4036/4885RAET1L 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.